Skip to main content
. 2016 Nov 1;6(11):2690–2699.

Figure 3.

Figure 3

TKT contributes to cisplatin chemoresistance in cervical cancer. (A) Protein level of TKT in specific TKT siRNA-treated HeLa and SiHa cells was measured by Western blotting. The cell viability (B) and caspase-3/7 activity (C) in TKT siRNA-treated HeLa and SiHa cells were measured in the presence of cisplatin. (D) Over-expression efficiency of TKT in HeLa and SiHa cells were measured by Western blotting. The cell viability (E) and caspase-3/7 activity (F) in TKT over-expressed HeLa and SiHa cells were measured in the presence of cisplatin. (G) Protein levels of TKT in the TKT-overexpressed or control cells upon miR-497 treatment was measured by Western blotting. The cell viability (H) and caspase-3/7 activity (I) in HeLa and SiHa cells with indicated treatment were measured in the presence of cisplatin; p value was calculated by comparing to NC. *P < 0.05, **P < 0.01; NS, not significant.